Efficacy of iGlarLixi, a fixed ‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - June 20, 2018 Category: Endocrinology Authors: Danny H. Sugimoto , Terry Dex , William Stager , Vanita R. Aroda Source Type: research